Eli Lilly, Pfizer, The Wellcome Trust, University College London, University of Oxford neurology, endocrine/metabolic news
The Wellcome Trust announced the first two projects to be funded under its Pathfinder Awards Scheme, which aims to build on or establish a partnership between academia or not-for-profits and a company to develop treatments for Orphan and neglected diseases. In the first project, Eli Lilly and researchers at the University College London will develop a pluripotent human stem cell line that can be used to study neurodegeneration with iron accumulation (NBIA), a neurological disorder with symptoms that include tremors, sustained muscle contractions and a decline in brain function.
In the second project, Pfizer and researchers at the Structural Genomics Consortium at the University of Oxford will investigate methods to restore normal metabolism and prevent progression of homocystinuria, a hereditary metabolic disorder. ...